Document Detail

Supramaximal doses of botulinum toxin for refractory blepharospasm.
MedLine Citation:
PMID:  16828511     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To investigate the response to supramaximal doses of botulinum toxin in patients with refractory blepharospasm. DESIGN: Prospective, nonrandomized, open-label interventional case series. PARTICIPANTS: Eight consecutive patients with blepharospasm requiring injections every 2 months despite receiving 100 U of botulinum toxin per session. INTERVENTION: Increasing the dose of botulinum toxin per session above the conventional maximum. MAIN OUTCOME MEASURES: Duration of treatment effect and patients' subjective response to treatment. RESULTS: Supramaximal dosages were well tolerated. Seven of 8 patients had a prolonged interval between injections relative to that associated with their previous dosing regimen. Four of the patients elected to continue with the new dosage. CONCLUSION: In select patients with essential blepharospasm who are refractory to standard treatment regimens, increasing the dosage of botulinum toxin above 100 U per session may decrease the interval between injections, improve the patient's quality of life, or both.
Richard L Levy; Dalia Berman; Mona Parikh; Neil R Miller
Publication Detail:
Type:  Journal Article     Date:  2006-07-07
Journal Detail:
Title:  Ophthalmology     Volume:  113     ISSN:  1549-4713     ISO Abbreviation:  Ophthalmology     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-09-04     Completed Date:  2006-09-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7802443     Medline TA:  Ophthalmology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1665-8     Citation Subset:  IM    
Neuro-ophthalmology Unit, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Blepharospasm / drug therapy*
Botulinum Toxin Type A / administration & dosage*
Injections, Intramuscular
Maximum Tolerated Dose
Middle Aged
Neuromuscular Agents / administration & dosage*
Prospective Studies
Reg. No./Substance:
0/Botulinum Toxin Type A; 0/Neuromuscular Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Metastatic retinoblastoma clinical features, treatment, and prognosis.
Next Document:  Complement factor H increases risk for atrophic age-related macular degeneration.